Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.50 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | CFB | P00751 | 2/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15831467 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL15831466 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL24775430 | 0.98 | CHRNB2 (0.51) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL24775157 | 0.98 | CHRNB2 (0.51) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL22473219 | 0.95 | CHRNB2 (0.59) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL13388673 | 0.95 | CHRNB2 (0.59) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL22473392 | 0.95 | CHRNB2 (0.59) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL11947314 | 0.87 | RIPK1 (0.53) | CHRNB2CHRNA7CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL22473531 | 0.83 | TRPA1 (0.44) | — | |
| SCHEMBL22473220 | 0.83 | TRPA1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230033360-A1 | COMPOUNDS AS CD73 INHIBITORS | BIOARDIS LLC | 2023-02-02 | — | — | US | disclosed |
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-9637493-B2 | Substituted pyrrolopyrimidines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9540377-B2 | 2,6,7,8 substituted purines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
| US-8962611-B2 | Substituted imidazopyridines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140357618-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME LLC | 2014-12-04 | — | — | US | disclosed |
| US-20090258858-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| US-20090258858-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-10-15 | — | — | US | disclosed |
| US-7531539-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | CHRNB2 4503/4885CHRNA7 4831/4885CHRNA4 4874/4885 |
| US-20230033360-A1 | COMPOUNDS AS CD73 INHIBITORS | ENTPD5, ENTPD1, NT5E | CHRNB2 1151/4885CHRNA7 1015/4885CHRNA4 992/4885 |
| US-20090258858-A1 | MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | CHRM3, CHRNG, CHRM2 | CHRNB2 11/4885CHRNA7 14/4885CHRNA4 15/4885 |
| US-10787446-B2 | Therapeutic compounds and methods of use thereof | AVPR1B, C3AR1, RHEB | CHRNB2 1972/4885CHRNA7 1555/4885CHRNA4 2525/4885 |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | DDX21, DPYD, NSUN2 | CHRNB2 4706/4885CHRNA7 4770/4885CHRNA4 4857/4885 |
| US-20140357618-A1 | SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | DDX21, ING2, MDM2 | CHRNB2 4780/4885CHRNA7 4870/4885CHRNA4 4862/4885 |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | CHRNB2 2180/4885CHRNA7 1622/4885CHRNA4 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.